Potential of cell-free nucleic acids as early disease markers - Riikka Lund

Finnish Functional Genomics Centre support high level research by developing, implementing and providing open access services and expertise support for the latest state-of-the art technologies and applications available for genome research. Our core facility services are open to all users and cover a full range of options depending on the needs of the service users.

We belong to the Biocenter Finland Genome-Wide Methods network. The infrastructure and research services provided by our core facility are supported by Biocenter Finland, Academy of Finland, University of Turku and Åbo Akademi University.
------------------------------------------------------------------------------------------------------------------------------------------------

Biomedical Epigenomics group explores, develops and implements the latest technologies and methods to study genomic and epigenomic regulation during early human development, aging and in diseases. By comparing and modelling epigenomes of healthy and diseased individuals with the latest cutting-edge methods our goal is to understand the mechanisms of the diseases, how they develop, find novel type of disease marker candidates and targets for drug development. By providing novel innovative approaches enabling prediction, early diagnosis and efficient precision treatment of diseases our ultimate goal is to promote lifelong health.